10 Best Immunology Stocks To Buy Now
Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.
Exelixis Inc. (EXEL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 23,439,500 | $780,535,350 | -8% | 3.95% |
| 2. | Renaissance Technologies Jim Simons | 15,295,865 | $509,352,305 | -1% | 0.75% |
| 3. | AQR Capital Management Cliff Asness | 3,967,005 | $132,101,266 | +26% | 0.17% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,159,395 | $105,207,854 | +105% | 0.08% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,627,890 | $54,208,737 | -5% | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.76 | 225,000 | Director | 1,525,730 | 2024-05-30 | Filing | |
| $20.32 | 200,000 | Director | 1,300,730 | 2024-05-28 | Filing | |
| $20.70 | 190,000 | Director | 1,100,730 | 2024-02-21 | Filing | |
| $21.61 | 120,409 | Director | 910,730 | 2023-11-27 | Filing | |
| $4.95 | 20,000 | Director | 568,273 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $38.80 | 10,000 | Officer | 341,028 | 2025-03-03 | Filing | |
| $37.62 | 19,294 | Director | 10,778 | 2025-02-28 | Filing | |
| $38.13 | 54,514 | Director | 10,778 | 2025-02-27 | Filing | |
| $37.80 | 8,768 | Director | 356,605 | 2025-02-28 | Filing | |
| $36.98 | 52,636 | Officer | 303,310 | 2025-02-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 30,316,051 | $1,009,524,497 | 0.02% | |
| 2. | 29,429,252 | $979,994,092 | 0.01% | |
| 3. | 11,411,943 | $380,017,702 | 0.01% | |
| 4. | 7,630,940 | $254,110,295 | 0.96% | |
| 5. | 5,157,809 | $171,805,936 | 0.01% |
News See All
Renaissance Technologies Portfolio: Top 10 Stock Picks
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.
Exelixis, Inc. (NASDAQ:EXEL) Q4 2024 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2024 Financial Results Conference Call. My name is Sherry, and I'll be your operator for today.
What Makes Exelixis (EXEL) an Investment Bet?
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Performing Biotech Stocks in 2024
The biotechnology sector is expanding quickly due to rising demand for novel therapies, advancement in technology, and government assistance.
Exelixis, Inc. (NASDAQ:EXEL) Q3 2024 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to Exelixis Third Quarter 2024 Financial Results Conference Call. My name is Towanda, and I will be your operator for today.
10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
Top 10 Holdings of Caligan Partners
Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.
Exelixis, Inc. (NASDAQ:EXEL) Q2 2024 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Second Quarter 2024 Financial Results Conference Call. My name is Tawanda and I'll be your operator for today.
Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript
Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28.
Billionaire Hedge Funds
